APOC3 and Combined hyperlipidemia: In a recent phase 2b, double-blind, randomized, placebo-controlled trial, plozasiran was administered every 12 weeks to patients with mixed hyperlipidemia.13 After 24 weeks, participants in the plozasiran arm exhibited 60% lower APOC3 levels, 62% lower triglyceride levels, 46% lower remnant cholesterol, 15% lower ApoB, 11% lower LDL-cholesterol, 30% higher HDL-cholesterol, and no difference in lipoprotein(a) when compared to the control group.13 The genetic associations show a similar pattern of associations with lipoprotein-lipids levels.